RCT: Nebulized Poractant Alfa in premature babies with respiratory distress syndrome.

A Randomized, Controlled Trial to Investigate the Efficacy of Nebulized Poractant Alfa in Premature Babies with Respiratory Distress Syndrome – The Journal of Pediatrics

Commentary: Should we give up on nebulised surfactant? – Neonatal Research

Commentary on Twitter

The CURONEB RCT by Dani et al. in @JPediatr stopped early, but showed that nebulised poractant alfa is safe but does not reduce respiratory failure within 72 hours in 28-33 weekers https://t.co/gW57rPTd4f #FOAMneo #EBNEOalerts #neoEBM #neotwitter pic.twitter.com/G5Cii33fRD

— Evidence-Based Neo (@EBNEO) March 8, 2022